Press Release Details

Investor Relations

GoHealth Reports Third Quarter 2021 Results

Nov 09, 2021 at 4:05 PM EST
Reaffirms Full-Year Guidance

CHICAGO, Nov. 9, 2021 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and nine months ended September 30, 2021.

  • Third quarter 2021 net revenue of $211.7 million increased 30% compared to the prior year period. YTD 2021 net revenue of $612.8 million increased 42% compared to the prior year period.
  • Third quarter 2021 Medicare—Internal revenue of $158.6 million increased 19% compared to the prior year period. YTD 2021 Medicare—Internal revenue of $476.4 million increased 51% compared to the prior year period.
  • Third quarter 2021 Medicare Advantage ("MA") Approved Submissions of 193,107 increased 100% compared to the prior year period. YTD 2021 MA Approved Submissions of 516,983 increased 67% compared to the prior year period.
  • Third quarter 2021 MA LTV Per Approved Submission of $926 decreased 6% compared to the prior year period. YTD 2021 MA LTV Per Approved Submission of $957 increased 5% compared to the prior year period.
  • Third quarter 2021 net loss of $55.4 million compared to a net loss of $206.5 million in the prior year period; Adjusted EBITDA1 of negative $14.1 million decreased 136% compared to the prior year period due to the 2021 strategic investments in agent capacity, marketplace technology, branding and the Encompass Platform. YTD 2021 net loss was $101.9 million compared to a net loss of $230.3 million in the prior year period; Adjusted EBITDA1 of $32.3 million decreased 68% compared to the prior year period.
  • The Company reaffirmed its full-year 2021 outlook, and expects total net revenue of $1,200 - $1,300 million (+37% to +48%) powered by commission net revenue of $1,000 - $1,100 million (+49% to +64%). The Company also reaffirms its Adjusted EBITDA1 outlook of $300 - $330 million (+11% to +22%).

Clint Jones, co-founder and CEO said, "During the third quarter, we delivered revenue growth of 30%, while also exceeding our agent hiring goals in preparation for a successful Annual Enrollment Period. We are excited about our ability to grow our membership base during AEP and deliver the trusted healthcare advice seniors need to navigate the increasingly complex Medicare market. This increase in our agent force will enable us to better serve more seniors during this year's AEP, grow our membership base and realize the potential of this enormous market opportunity. As a result of our agent hiring and momentum in our Encompass Platform, we are reaffirming our full-year 2021 guidance."

Third Quarter 2021 Highlights2

  • Total company revenue grew 30% to $211.7 million, net of a $6.7 million negative revenue adjustment relating to revenue estimates from prior periods
  • Medicare—Internal net revenue increased 19% to $158.6 million
  • LTV Per carrier Approved MA Submission decreased 6% to $926
  • Adjusted EBITDA1 decreased 136% to negative $14.1 million
    • Investment in customer care and enrollment grew to $87.8 million, an increase of 112% excluding non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO in prior year results, which primarily represents the costs to hire and onboard agents in advance of the Annual Enrollment Period ("AEP")
      • Agent counts grew well ahead of the 50% target as the Company prepares for the AEP and fiscal 2022
    • Total cost of revenue, marketing and advertising expense grew 28%, roughly in line with sales growth

YTD 2021 Highlights2

  • Total company revenue grew 42% to $612.8 million
  • Medicare—Internal net revenue increased 51% to $476.4 million
  • LTV Per carrier Approved MA Submission increased 5% to $957
  • Adjusted EBITDA1 decreased 68% to $32.3 million
    • Investment in customer care and enrollment grew to $196.8 million, an increase of 110% excluding non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO in prior year results, which primarily represents the costs to hire and onboard agents in advance of the AEP
    • Total cost of revenue, marketing and advertising expense grew 44%, roughly in line with sales growth

2021 Financial Outlook

The trajectory of the U.S. economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. The Company is reaffirming its financial outlook for the fiscal year ending December 31, 2021 based on current market conditions and expectations:

  • Full-year 2021 net revenue of $1,200 - $1,300 million, representing year-over-year growth of 37% - 48%
    • Full-year 2021 commission revenue of $1,000 - $1,100 million, representing year-over-year growth of 49% - 64%, fueled by the Company's continued investment in its Medicare business, including GoHealth's Encompass Platform
  • Full-year 2021 Adjusted EBITDA1 of $300 - $330 million, representing year-over-year growth of 11% - 22%
 

Conference Call Details

The Company will host a conference call today, Tuesday, November 9, 2021 at 5:00 p.m. (ET) to discuss its financial results.  A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 2553159. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

About GoHealth, Inc.:

As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. GoHealth has enrolled millions of people in Medicare plans and individual and family plans. For more information, visit https://www.gohealth.com.

Investor Relations:
IR@gohealth.com

Media Relations:
Pressinquiries@gohealth.com

 

(1)

Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

(2)

Third quarter and YTD 2021 results compared to the comparable prior year period.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected financial performance and operational performance for the fiscal year 2021, including with respect to revenue and Adjusted EBITDA, the growth of our membership base, and our ability to realize the potential of our market opportunity are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but are not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationship; failure to grow the Company's customer base or retain its existing customers; the time and cost of training agents are significant and can increase during a period of high attrition; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; significant consolidation in the healthcare industry which could adversely alter the Company's relationships with carriers; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; changes in the health insurance system and laws and regulation governing health insurance markets; the inability to effectively advertise the Company's products; and our ability to successfully implement our business plan during a global economic downturn caused by the COVID-19 pandemic.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Use of Non-GAAP Financial Measures and Key Performance Indicators

In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense ("EBITDA"); Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

Management has provided its outlook regarding Adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Reconciliations of Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), is presented in the table below in this press release.

Glossary

"Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, accelerated vesting of certain equity awards, loss on extinguishment of debt, loss on sublease, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs.

"Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

"Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

"LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

"Revenue Per Submission" refers to the total net revenues per Submitted Policy, which we define as (i) total net revenue, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of Submitted Policies for such period.

"Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

The following tables set forth the components of our results of operations for the periods indicated (unaudited):

(in thousands, except percentages and per share amounts)

 

Three months ended Sep.
30, 2021

 

Three months ended Sep.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$

174,948

   

82.6

%

 

$

101,390

   

62.1

%

 

$

73,558

   

72.5

%

Enterprise

 

36,786

   

17.4

%

 

61,970

   

37.9

%

 

(25,184)

   

(40.6)

%

Net revenues

 

211,734

   

100.0

%

 

163,360

   

100.0

%

 

48,374

   

29.6

%

Operating expenses:

                       

Cost of revenue

 

53,632

   

25.3

%

 

25,827

   

15.8

%

 

27,805

   

107.7

%

Marketing and advertising

 

59,511

   

28.1

%

 

62,848

   

38.5

%

 

(3,337)

   

(5.3)

%

Customer care and enrollment

 

87,813

   

41.5

%

 

52,896

   

32.4

%

 

34,917

   

66.0

%

Technology

 

11,651

   

5.5

%

 

39,520

   

24.2

%

 

(27,869)

   

(70.5)

%

General and administrative

 

24,232

   

11.4

%

 

156,551

   

95.8

%

 

(132,319)

   

(84.5)

%

Amortization of intangible assets

 

23,514

   

11.1

%

 

23,514

   

14.4

%

 

   

%

Total operating expenses

 

260,353

   

123.0

%

 

361,156

   

221.1

%

 

(100,803)

   

(27.9)

%

Income (loss) from operations

 

(48,619)

   

(23.0)

%

 

(197,796)

   

(121.1)

%

 

149,177

   

(75.4)

%

Interest expense

 

6,921

   

3.3

%

 

8,636

   

5.3

%

 

(1,715)

   

(19.9)

%

Loss on extinguishment of debt

 

   

%

 

   

%

 

   

N/M

Other (income) expense

 

(30)

   

%

 

2

   

%

 

(32)

   

N/M

Income (loss) before income taxes

 

(55,510)

   

(26.2)

%

 

(206,434)

   

(126.4)

%

 

150,924

   

(73.1)

%

Income tax expense (benefit)

 

(79)

   

%

 

62

   

%

 

(141)

   

N/M

Net income (loss)

 

$

(55,431)

   

(26.2)

%

 

$

(206,496)

   

(126.4)

%

 

$

151,065

   

(73.2)

%

Net income (loss) attributable to noncontrolling interests

 

(35,248)

   

(16.6)

%

 

(150,076)

   

(91.9)

%

 

114,828

   

N/M

Net income (loss) attributable to GoHealth, Inc.

 

$

(20,183)

   

(9.5)

%

 

$

(56,420)

   

(34.5)

%

 

$

36,237

   

(64.2)

%

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted (1)

 

$

(0.18)

       

$

(0.65)

             

Weighted-average shares of Class A common stock outstanding — basic and diluted

 

113,938

       

84,183

             

Non-GAAP financial measures:

                       

EBITDA

 

$

(22,519)

       

$

(173,021)

             

Adjusted EBITDA

 

$

(14,068)

       

$

39,284

             

Adjusted EBITDA margin

 

(6.6)

%

     

24.0

%

           
           

NM = Not meaningful

(1)

Net loss per share of Class A common stock—basic and diluted is the same for both the three and nine months ended September 30, 2020 as both periods are based on the post-IPO net loss from July 17, 2020 to September 30, 2020.

 

(in thousands, except percentages and per share amounts)

 

Nine months ended Sep.
30, 2021

 

Nine months ended Sep.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$

496,437

   

81.0

%

 

$

310,506

   

72.0

%

 

$

185,931

   

59.9

%

Enterprise

 

116,378

   

19.0

%

 

120,921

   

28.0

%

 

(4,543)

   

(3.8)

%

Net revenues

 

612,815

   

100.0

%

 

431,427

   

100.0

%

 

181,388

   

42.0

%

Operating expenses:

                       

Cost of revenue

 

139,449

   

22.8

%

 

104,520

   

24.2

%

 

34,929

   

33.4

%

Marketing and advertising

 

169,730

   

27.7

%

 

110,556

   

25.6

%

 

59,174

   

53.5

%

Customer care and enrollment

 

196,834

   

32.1

%

 

105,267

   

24.4

%

 

91,567

   

87.0

%

Technology

 

33,251

   

5.4

%

 

49,818

   

11.5

%

 

(16,567)

   

(33.3)

%

General and administrative

 

69,176

   

11.3

%

 

177,400

   

41.1

%

 

(108,224)

   

(61.0)

%

Change in fair value of contingent consideration liability

 

   

%

 

19,700

   

4.6

%

 

(19,700)

   

N/M

Amortization of intangible assets

 

70,543

   

11.5

%

 

70,543

   

16.4

%

 

   

%

Total operating expenses

 

678,983

   

110.8

%

 

637,804

   

147.8

%

 

41,179

   

6.5

%

Income (loss) from operations

 

(66,168)

   

(10.8)

%

 

(206,377)

   

(47.8)

%

 

140,209

   

(67.9)

%

Interest expense

 

23,886

   

3.9

%

 

24,378

   

5.7

%

 

(492)

   

(2.0)

%

Loss on extinguishment of debt

 

11,935

   

1.9

%

 

   

%

 

11,935

   

N/M

Other (income) expense

 

27

   

%

 

(494)

   

(0.1)

%

 

521

   

(105.5)

%

Income (loss) before income taxes

 

(102,016)

   

(16.6)

%

 

(230,261)

   

(53.4)

%

 

128,245

   

(55.7)

%

Income tax expense (benefit)

 

(142)

   

%

 

38

   

%

 

(180)

   

N/M

Net income (loss)

 

$

(101,874)

   

(16.6)

%

 

$

(230,299)

   

(53.4)

%

 

$

128,425

   

(55.8)

%

Net loss attributable to noncontrolling interests

 

(67,612)

   

(11.0)

%

 

(150,076)

   

(34.8)

%

 

$

82,464

   

(54.9)

%

Net loss attributable to GoHealth, Inc.

 

$

(34,262)

   

(5.6)

%

 

$

(80,223)

   

(18.6)

%

 

$

45,961

   

(57.3)

%

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted (1)

 

$

(0.33)

       

$

(0.65)

             

Weighted-average shares of Class A common stock outstanding — basic and diluted

 

102,939

       

84,183

             

Non-GAAP financial measures:

                       

EBITDA

 

$

(955)

       

$

(132,441)

             

Adjusted EBITDA

 

$

32,322

       

$

101,141

             

Adjusted EBITDA margin

 

5.3

%

     

23.4

%

           
           

NM = Not meaningful

(1)

Net loss per share of Class A common stock—basic and diluted is the same for both the three and nine months ended September 30, 2020 as both periods are based on the post-IPO net loss from July 17, 2020 to September 30, 2020.

 

The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

(in thousands)

 

Three months
ended Sep.
30, 2021

 

Three months
ended Sep.
30, 2020

Net revenues

 

$

211,734

   

$

163,360

 

Net income (loss)

 

(55,431)

   

(206,496)

 

Interest expense

 

6,921

   

8,636

 

Income tax expense (benefit)

 

(79)

   

62

 

Depreciation and amortization expense

 

26,070

   

24,777

 

EBITDA

 

(22,519)

   

(173,021)

 

Share-based compensation expense (1)

 

7,389

   

2,770

 

Accelerated vesting of certain equity awards (2)

 

   

209,300

 

Loss on sublease (3)

 

1,062

   

 

IPO transaction costs (4)

 

   

235

 

Adjusted EBITDA

 

$

(14,068)

   

$

39,284

 

Adjusted EBITDA margin

 

(6.6)

%

 

24.0

%

           

(1)

Represents non-cash share-based compensation expense relating to equity awards.

(2)

Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the three months ended September 30, 2020.

(3)

Represents the loss related to a sublease agreement entered into during the three months ended September 30, 2021.

(4)

Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

 

(in thousands)

 

Nine months
ended Sep.
30, 2021

 

Nine months
ended Sep.
30, 2020

Net revenues

 

$

612,815

   

$

431,427

 

Net income (loss)

 

(101,874)

   

(230,299)

 

Interest expense

 

23,886

   

24,378

 

Income tax expense (benefit)

 

(142)

   

38

 

Depreciation and amortization expense

 

77,175

   

73,442

 

EBITDA

 

(955)

   

(132,441)

 

Loss on extinguishment of debt (1)

 

11,935

   

 

Share-based compensation expense (2)

 

20,100

   

3,846

 

Accelerated vesting of certain equity awards (3)

 

   

209,300

 

Loss on sublease (4)

 

1,062

   

 

Legal fees (5)

 

180

   

 

Change in fair value of contingent consideration liability (6)

 

   

19,700

 

IPO transaction costs (7)

 

   

659

 

Severance costs (8)

 

   

77

 

Adjusted EBITDA

 

$

32,322

   

$

101,141

 

Adjusted EBITDA margin

 

5.3

%

 

23.4

%

           

(1)

Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

(2)

Represents non-cash share-based compensation expense relating to equity awards.

(3)

Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the nine months ended September 30, 2020.

(4)

Represents the loss related to a sublease agreement entered into during the nine months ended September 30, 2021.

(5)

Represents non-recurring legal fees unrelated to our core operations.

(6)

Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

(7)

Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

(8)

Represents costs associated with the termination of employment.

 

The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

(in thousands)

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Marketing and advertising

 

$

698

   

$

24,709

   

$

1,462

   

$

24,829

 

Customer care and enrollment

 

957

   

11,993

   

2,796

   

12,050

 

Technology

 

910

   

32,748

   

2,791

   

32,907

 

General and administrative

 

4,824

   

142,620

   

13,051

   

143,360

 

Total share-based compensation expense

 

$

7,389

   

$

212,070

   

$

20,100

   

$

213,146

 
 

The following table sets forth our balance sheets for the periods indicated (unaudited):

(in thousands, except per share amounts)

 

Sep. 30, 2021

 

Dec. 31, 2020

Assets

       

Current assets:

       

Cash and cash equivalents

 

$

85,221

   

$

144,234

 

Accounts receivable, net of allowance for doubtful accounts of $634 in 2021 and $787 in 2020

 

8,578

   

14,211

 

Receivable from NVX Holdings, Inc.

 

   

3,395

 

Commissions receivable - current

 

133,422

   

188,128

 

Prepaid expense and other current assets

 

29,291

   

41,854

 

Total current assets

 

256,512

   

391,822

 

Commissions receivable - non-current

 

837,958

   

622,270

 

Other long-term assets

 

3,988

   

2,072

 

Property, equipment, and capitalized software, net

 

27,424

   

17,353

 

Intangible assets, net

 

618,183

   

688,726

 

Goodwill

 

386,553

   

386,553

 

Total assets

 

$

2,130,618

   

$

2,108,796

 

Liabilities and Stockholders' Equity

       

Current liabilities:

       

Accounts payable

 

$

24,297

   

$

8,733

 

Accrued liabilities

 

32,737

   

26,926

 

Commissions payable - current

 

60,303

   

78,478

 

Deferred revenue

 

561

   

736

 

Current portion of long-term debt

 

4,270

   

4,170

 

Other current liabilities

 

10,764

   

8,328

 

Total current liabilities

 

132,932

   

127,371

 

Non-current liabilities:

       

Commissions payable - non-current

 

237,005

   

182,596

 

Long-term debt, net of current portion

 

439,216

   

396,400

 

Other non-current liabilities

 

3,676

   

3,274

 

Total non-current liabilities

 

679,897

   

582,270

 

Stockholders' equity:

       

Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 114,713 and 84,196 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.

 

11

   

8

 

Class B common stock – $0.0001 par value; 588,002 and 619,004 shares authorized; 205,995 and 236,997 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.

 

21

   

24

 

Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at September 30, 2021 and December 31, 2020.

 

   

 

Additional paid-in capital

 

550,455

   

399,169

 

Accumulated other comprehensive income (loss)

 

(4)

   

17

 

Accumulated deficit

 

(53,064)

   

(18,802)

 

Total stockholders' equity attributable to GoHealth, Inc.

 

497,419

   

380,416

 

Non-controlling interests

 

820,370

   

1,018,739

 

Total stockholders' equity

 

1,317,789

   

1,399,155

 

Total liabilities and stockholders' equity

 

$

2,130,618

   

$

2,108,796

 

The following table sets forth our statements of cash flows for the periods indicated (unaudited):

(in thousands)

 

Nine months
ended Sep.
30, 2021

 

Nine months
ended Sep.
30, 2020

Operating Activities

       

Net income (loss)

 

$

(101,874)

   

$

(230,299)

 

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

       

Share-based compensation

 

20,100

   

213,146

 

Depreciation and amortization

 

6,632

   

2,899

 

Amortization of intangible assets

 

70,543

   

70,543

 

Amortization of debt discount and issuance costs

 

1,696

   

1,744

 

Change in fair value of contingent consideration

 

   

19,700

 

Loss on extinguishment of debt

 

11,935

   

 

Loss on sublease

 

1,062

   

 

Other non-cash items

 

(708)

   

(1,100)

 

Changes in assets and liabilities, net of acquisition:

       

Accounts receivable

 

6,173

   

14,860

 

Commissions receivable

 

(160,982)

   

(117,888)

 

Prepaid expenses and other assets

 

10,471

   

(10,884)

 

Accounts payable

 

18,298

   

(4,402)

 

Accrued liabilities

 

5,693

   

(1,793)

 

Deferred revenue

 

(175)

   

40,188

 

Commissions payable

 

36,233

   

27,983

 

Other liabilities

 

2,484

   

4,138

 

Net cash provided by (used in) operating activities

 

(72,419)

   

28,835

 

Investing Activities

       

Purchases of property, equipment and software

 

(19,269)

   

(12,023)

 

Net cash used in investing activities

 

(19,269)

   

(12,023)

 

Financing Activities

       

Proceeds from issuance of Class A common stock sold in initial public offering, net of offering costs

 

   

852,407

 

Payment of partial consideration of the Blocker Merger

 

   

(96,165)

 

Purchase of LLC Interests

 

   

(508,320)

 

Settlement of Senior Preferred Earnout Units

 

   

(100,000)

 

Proceeds received upon issuance of common units

 

   

10,000

 

Borrowings under term loans

 

335,000

   

117,000

 

Payments of term loans

 

(297,903)

   

(2,835)

 

Call premium paid for debt extinguishment

 

(5,910)

   

 

Debt issuance cost payments

 

(1,608)

   

(6,291)

 

Principal payments under capital lease obligations

 

(231)

   

(218)

 

Cash received on advancement to NVX Holdings, Inc.

 

3,395

   

 

Net cash provided by financing activities

 

32,743

   

265,578

 

Effect of exchange rate changes on cash and cash equivalents

 

(68)

   

(68)

 

Increase in cash and cash equivalents

 

(59,013)

   

282,322

 

Cash and cash equivalents at beginning of period

 

144,234

   

12,276

 

Cash and cash equivalents at end of period

 

$

85,221

   

$

294,598

 

Supplemental Disclosure of Cash Flow Information

       

Non-cash investing and financing activities:

       

Purchases of property, equipment and software included in accounts payable

 

$

2,734

   

$

1,104

 

Issuance of senior preferred earnout units to settle contingent consideration liability

 

$

   

$

100,000

 

Issuance of common A and B units to settle contingent consideration liability

 

$

   

$

100,000

 

Issuance of Class A and Class B common stock in connection with Reorganization Transactions

 

$

   

$

30

 

Settlement of contingent consideration liability

 

$

   

$

62,400

 

The following tables set forth operating segment results for the periods indicated (unaudited):

(in thousands, except percentages)

 

Three months ended Sep.
30, 2021

 

Three months ended Sep.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$

158,605

   

74.9

%

 

$

133,723

   

82.0

%

 

$

24,882

   

18.6

%

Medicare - External

 

46,237

   

21.8

%

 

20,252

   

12.4

%

 

25,985

   

128.3

%

IFP and Other - Internal

 

5,742

   

2.7

%

 

6,147

   

3.8

%

 

(405)

   

(6.6)

%

IFP and Other - External

 

1,150

   

0.5

%

 

3,238

   

2.0

%

 

(2,088)

   

(64.5)

%

Net revenues

 

211,734

   

100.0

%

 

163,360

   

100.0

%

 

48,374

   

29.6

%

Segment profit (loss):

                       

Medicare - Internal

 

(4,126)

   

(1.9)

%

 

49,464

   

30.3

%

 

(53,590)

   

(108.3)

%

Medicare - External

 

1,866

   

0.9

%

 

720

   

0.4

%

 

1,146

   

N/M

IFP and Other - Internal

 

2,186

   

1.0

%

 

(245)

   

(0.1)

%

 

2,431

   

N/M

IFP and Other - External

 

(330)

   

(0.2)

%

 

147

   

0.1

%

 

(477)

   

(324.5)

%

Segment profit (loss)

 

(404)

   

(0.2)

%

 

50,086

   

30.7

%

 

(50,490)

   

(100.8)

%

Corporate expense

 

24,701

   

11.7

%

 

224,368

   

137.3

%

 

(199,667)

   

(89.0)

%

Amortization of intangible assets

 

23,514

   

11.1

%

 

23,514

   

14.4

%

 

   

%

Interest expense

 

6,921

   

3.3

%

 

8,636

   

5.3

%

 

(1,715)

   

(19.9)

%

Other (income) expense

 

(30)

   

%

 

2

   

%

 

(32)

   

N/M

Income (loss) before income taxes

 

$

(55,510)

   

(26.2)

%

 

$

(206,434)

   

(126.4)

%

 

$

150,924

   

(73.1)

%

           

NM = Not meaningful

 

   

Nine months ended Sep.
30, 2021

 

Nine months ended Sep.
30, 2020

       

(in thousands, except percentages)

 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$

476,391

   

77.7

%

 

$

316,211

   

73.3

%

 

$

160,180

   

50.7

%

Medicare - External

 

117,116

   

19.1

%

 

77,305

   

17.9

%

 

39,811

   

51.5

%

IFP and Other - Internal

 

13,505

   

2.2

%

 

21,798

   

5.1

%

 

(8,293)

   

(38.0)

%

IFP and Other - External

 

5,803

   

0.9

%

 

16,113

   

3.7

%

 

(10,310)

   

(64.0)

%

Net revenues

 

612,815

   

100.0

%

 

431,427

   

100.0

%

 

181,388

   

42.0

%

Segment profit (loss):

                       

Medicare - Internal

 

73,574

   

12.0

%

 

123,946

   

28.7

%

 

(50,372)

   

(40.6)

%

Medicare - External

 

(453)

   

(0.1)

%

 

892

   

0.2

%

 

(1,345)

   

N/M

IFP and Other - Internal

 

657

   

0.1

%

 

181

   

%

 

476

   

N/M

IFP and Other - External

 

(227)

   

%

 

789

   

0.2

%

 

(1,016)

   

(128.8)

%

Segment profit (loss)

 

73,551

   

12.0

%

 

125,808

   

29.2

%

 

(52,257)

   

(41.5)

%

Corporate expense

 

69,176

   

11.3

%

 

241,942

   

56.1

%

 

(172,766)

   

(71.4)

%

Change in fair value of contingent consideration liability

 

   

%

 

19,700

   

4.6

%

 

(19,700)

   

N/M

Amortization of intangible assets

 

70,543

   

11.5

%

 

70,543

   

16.4

%

 

   

%

Loss on extinguishment of debt

 

11,935

   

1.9

%

 

   

%

 

11,935

   

N/M

Interest expense

 

23,886

   

3.9

%

 

24,378

   

5.7

%

 

(492)

   

(2.0)

%

Other (income) expense

 

27

   

%

 

(494)

   

(0.1)

%

 

521

   

(105.5)

%

Income (loss) before income taxes

 

$

(102,016)

   

(16.6)

%

 

$

(230,261)

   

(53.4)

%

 

$

128,245

   

(55.7)

%

           

NM = Not meaningful

 

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020, for those submissions that are commissionable (compensated through commissions received from carriers):

Medicare - Total Commissionable Submitted Policies

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Medicare Advantage

 

149,680

 

97,675

 

475,717

 

314,088

Medicare Supplement

 

648

 

1,245

 

2,774

 

6,164

Prescription Drug Plans

 

1,923

 

2,006

 

6,890

 

6,437

Total Medicare

 

152,251

 

100,926

 

485,381

 

326,689

The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for three and nine months ended September 30, 2021 and 2020. Only commissionable policies are used to calculate LTV.

Medicare - Internal Commissionable Approved Submissions

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Medicare Advantage

 

145,619

 

77,186

 

395,804

 

228,612

Medicare Supplement

 

183

 

315

 

702

 

1,602

Prescription Drug Plans

 

2,208

 

1,574

 

6,525

 

5,319

Total Medicare

 

148,010

 

79,075

 

403,031

 

235,533

 
 

Medicare - External Commissionable Approved Submissions

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Medicare Advantage

 

47,488

 

19,390

 

121,179

 

80,656

Medicare Supplement

 

427

 

844

 

1,823

 

4,035

Prescription Drug Plans

 

191

 

352

 

716

 

1,206

Total Medicare

 

48,106

 

20,586

 

123,718

 

85,897

The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020:

LTV per Approved Submission

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Medicare Advantage

 

$

926

 

$

987

 

$

957

 

$

913

Medicare Supplement

 

$

874

 

$

934

 

$

834

 

$

929

Prescription Drug Plans

 

$

215

 

$

215

 

$

215

 

$

216

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and nine months ended September 30, 2021 and 2020, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:

Medicare - Total Non-Commissionable Submitted Policies

 

Three
months
ended Sep.
30, 2021

 

Three
months
ended Sep.
30, 2020

 

Nine
months
ended Sep.
30, 2021

 

Nine
months
ended Sep.
30, 2020

Medicare Advantage

 

1,532

 

6,472

 

10,703

 

20,806

Medicare Supplement

 

1,327

 

1,716

 

5,019

 

5,262

Prescription Drug Plans

 

542

 

1,034

 

2,218

 

2,787

Total Medicare

 

3,401

 

9,222

 

17,940

 

28,855

The following table presents a reconciliation from net income to non-GAAP Adjusted EBITDA guidance for the twelve months ended December 31, 2021:

   

Twelve months ended

Dec. 31, 2021

   

Guidance Range

(in thousands)

 

Low

 

High

Net revenues

 

$

1,200,000

   

$

1,300,000

 

Net income

 

126,603

   

156,603

 

Interest expense

 

30,000

   

30,000

 

Income tax expense

 

220

   

220

 

Depreciation and amortization expense

 

102,000

   

102,000

 

EBITDA

 

258,823

   

288,823

 

Loss on extinguishment of debt (1)

 

11,935

   

11,935

 

Share-based compensation expense (2)

 

28,000

   

28,000

 

Loss on sublease (3)

 

1,062

   

1,062

 

Legal fees (4)

 

180

   

180

 

Adjusted EBITDA

 

$

300,000

   

$

330,000

 

Adjusted EBITDA margin

 

25

%

 

25

%

           

(1)

Represents the loss on debt extinguishment related to the Term Loan Facility.

(2)

Represents non-cash share-based compensation expense relating to equity awards.

(3)

Represents the loss related to a sublease agreement.

(4)

Represents non-recurring legal fees unrelated to our core operations.

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gohealth-reports-third-quarter-2021-results-301420386.html

SOURCE GoHealth, Inc.

Our Awards